On November 13th, the standardized diagnosis and treatment competition of immunotherapy-related adverse reactions (irAEs) jointly carried out by crTOG of China Radiation Oncology Alliance and Shandong Clinical Oncology Society was held in Jinan. Zhang Jing, attending physician of Shandong Provincial Public Health Clinical Center, performed prominently in the finals and won the third prize in the national finals of the immunotherapy-related adverse reactions (irAEs) standardized diagnosis and treatment competition.
In recent years, tumor immunotherapy has become the focus of tumor treatment, and immunotherapy has made important progress in melanoma, lung cancer, head and neck cancer, esophageal cancer, stomach cancer, liver cancer, colorectal cancer, kidney cancer and most types of tumors. Immune checkpoint inhibitors such as PD-1, PD-L1, and CTLA4 produce immune-related adverse events (irAEs) while producing anti-tumor effects, and most irAEs are reversible if they can be found and correctly treated in time. In order to promote the correct understanding and standardized treatment of irAEs by the majority of physicians, the China Radiation Oncology Alliance and the Shandong Clinical Oncology Society jointly launched the irAEs standardized diagnosis and treatment competition.
It is understood that the competition was organized by the organizing committee to select relevant experts nationwide, and the preliminary selection produced sixteen strongest, and then eight excellent cases were selected to enter the professional review final. Zhang Jing, attending physician of the fourth ward of the Department of Respiratory and Critical Care Medicine of Shandong Provincial Public Health Clinical Center, under the guidance of Yu Xueyan, director of the department and chief physician, successfully promoted to the top eight in the country by virtue of the typicality of the case and the standardization of treatment. In the final, she performed well and won the third prize.
The case is a case of extensive small cell lung cancer patient, the first diagnosis of the left lung and a large number of pericardial effusions, left pleural effusion, cranial metastases, after the traditional treatment of standardized treatment, after the application of immunotherapy in January 2021, immune-related myocarditis appeared, Yu Xueyan's team made a rapid diagnosis, timely administration of immune trio-oxygen autologous blood transfusion, high-dose glucocorticoid impact, immunoglobulin infusion and other comprehensive treatment, the patient turned critical, myocarditis was finally reversed, Saved a happy and happy family.
The four wards of the Department of Respiratory and Critical Care Medicine of the Center specialize in the comprehensive treatment of tumors, and have rich clinical experience in chemotherapy, targeted therapy, anti-angiogenesis therapy and immunotherapy, and treatment of tumor co-infection of common tumors. The department actively introduces green therapies such as radiofrequency hyperthermia, immune three-carotid blood transfusion, and hydrogen-oxygen atomization inhalation to further improve tumor treatment methods and improve the effect of tumor treatment. At the same time, it pays attention to the psychological care of tumor patients, nutritional support treatment for patients with advanced tumors and standardized treatment of cancer pain, so that patients are satisfied. (Shi Xiaohong Zhang Jing)
Find reporters, reports, ask for help, major application markets download "Qilu OnePoint" APP or search weChat Mini Program "OnePoint Intelligence Station", more than 600 mainstream media reporters in the province are waiting for you to report online!